Evexia Lifecare reported a 25.7% revenue growth to Rs 105.46 crore for FY 2025-26, with profit after tax rising 108.9% to Rs 1.52 crore. However, the company faces a qualified audit opinion citing asset valuation, investment impairment risks, and persistent regulatory compliance failures leading to BSE fines. Shareholders should note the significant governance and internal control challenges.
Evexia Lifecare Posts Profit Growth Amid Audit Qualifications
Revenue rose 25.7% to Rs 105.46 crore while Profit After Tax (PAT) grew 108.9% to Rs 1.52 crore.
Reader Takeaway: Strong top-line performance is clouded by auditor-flagged asset risks and consistent regulatory compliance gaps at the company.
What just happened
Evexia Lifecare has released its financial results for FY 2025-26, showcasing a robust increase in profitability and revenue. However, the accompanying statutory audit report contains a 'Qualified Opinion,' signaling significant concerns regarding the company's financial reporting and internal controls. The management has also sought shareholder approval for related-party transactions with a cap of Rs 200 crore per annum per entity for the upcoming fiscal year.
Why this matters
While the financial numbers indicate growth, the auditor has flagged critical issues including the absence of a proper fixed asset register and a failure to perform impairment testing on investments worth Rs 711.31 crore. Additionally, the auditor highlighted concerns about the viability of subsidiaries like Kavit Edible Oil, which has been non-operational since 2019, and identified missing documentation for major tax expenses. These factors raise questions about the accuracy of the financial statements.
Regulatory and Governance Issues
The company’s transparency is further under scrutiny due to multiple compliance failures during the year, which resulted in fines paid to the BSE. These include persistent delays in filing financial results, failure to maintain mandatory Structured Digital Database (SDD) records, and prolonged vacancies in critical roles such as the Company Secretary and Compliance Officer.
Risks to watch
Investors should closely watch how the management addresses the auditor's concerns, particularly regarding the valuation of trade receivables (Rs 29.44 crore) and the potential impairment of long-term investments. The company's ability to maintain a stable compliance framework and fill key leadership positions will be critical for restoring investor confidence.
What to track next
Monitor upcoming filings for progress reports on the internal review of credit risks and updates on board composition. Shareholders should specifically review the management's plan to resolve the audit qualification before the next annual general meeting.